English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Psilocybin Therapy in Oregon: What Legal Access Actually Looks Like
A few years back, the idea of legally sitting with psilocybin mushrooms — in a licensed space, with a trained facilitator, without breaking any laws — sounded like wishful thinking. Then Oregon happened. In November 2020, voters there passed Measure 109, and the state became the first in the U.S. to create a regulated framework for supervised psilocybin use. The rollout has been slow, messy, and fascinating. And if you're someone weighing whether psychedelics might help with depression, trauma, or just a stuck patch of life, what's unfolded in Oregon matters. This isn't a political post. It's a practical one. I want to walk through what Oregon actually legalized, how it fits into the broader psychedelic renaissance, where it leaves people who can't fly to Portland, and what to keep in mind if you're considering plant medicine or psilocybin in a retreat setting. There's a lot of hype out there. The reality is more interesting — and more nuanced — than the headlines suggest. Here's the short version. Measure 109 didn't make psilocybin legal in the way alcohol or cannabis is legal in some states. You can't walk into a dispensary and buy dried mushrooms. You can't grow them at home for personal use without risk. What the measure created was a tightly controlled service model: licensed facilitators, licensed service centers, and clients who go through a preparation session, a dosing session, and an integration session — all on-site, all supervised. You don't need a diagnosis to participate. That's a meaningful detail. Unlike most clinical trials, where you have to qualify with treatment-resistant depression or end-of-life anxiety, Oregon's framework treats psilocybin services as a wellness offering open to adults. Whether that's a feature or a bug depends on who you ask. The state's Psilocybin Services program took its time to write the rules. The first licensed service centers opened in 2023, and as of 2026 there's a working — if still small — network of providers across the state. Prices for a full session run from about $1,500 to $3,500, sometimes more, which is a real barrier and one of the loudest criticisms from advocates who pushed for decriminalization instead of (or alongside) legalization. Oregon didn't happen in a vacuum. For years, researchers at Johns Hopkins, NYU, Imperial College London, and elsewhere have been publishing studies showing that psilocybin — given in a supportive setting, with proper preparation — can produce striking reductions in depression and anxiety, including in people who haven't responded to conventional treatment. The cancer-patient studies got the most press, but the work on major depression and on alcohol-use disorder has been just as compelling. That research is what cracked the door open. Decriminalization measures in Denver, Oakland, Santa Cruz, Ann Arbor, and a growing list of other cities pushed it open further. Then Oregon legalized supervised access. Colorado followed with Proposition 122 in 2022, which created its own regulated framework plus broader decriminalization of several plant medicines, including DMT and mescaline. The picture across the U.S. is now a patchwork. Federally, psilocybin remains a Schedule I substance. State by state, city by city, the rules shift. If you're researching options, the legal landscape where you live is worth checking carefully — not because anyone's likely to kick down your door, but because where the law sits affects which providers operate openly, what kind of training they've had, and what recourse you have if something goes wrong. People imagine a lot of things when they hear “legal mushroom therapy.” The reality is quieter than the imagination. A typical session at an Oregon service center looks something like this: It's not a party. It's not a quick fix. People who walk in expecting fireworks sometimes leave underwhelmed; people who walk in with humility and a real question often leave changed. Your experience depends on dose, set, setting, and frankly your nervous system on the day. The medicine doesn't perform on demand. If you're researching psychedelic options seriously, you've probably noticed that psilocybin isn't the only path on the table. Ayahuasca retreats in Peru, Costa Rica, and increasingly in legally permissive corners of Europe; ibogaine clinics in Mexico for people working through opioid addiction; San Pedro and huachuma ceremonies in the Andes; psilocybin retreats in Jamaica, the Netherlands, and now Oregon. Each tradition carries its own culture, its own risks, its own kind of work. Psilocybin tends to be the gentler doorway. The experience is usually shorter, the body load lighter, the integration arc more manageable for first-timers. Ayahuasca is longer, more physical (yes, the purging is real), and rooted in lineages worth understanding before you sign up. Ibogaine is a different animal entirely — powerful for addiction interruption, but with real cardiac risks that require medical screening. The point isn't to rank them. The point is that the choice should match what you're actually working on. Someone navigating grief and mild depression might find a supervised psilocybin session to be exactly the right size. Someone wrestling with deep generational trauma or long-term substance dependence might be better served by a longer-format plant-medicine retreat with experienced facilitators. There's no universal answer here. Whether you end up booking a psilocybin session in Oregon, an ayahuasca retreat in the Sacred Valley, or something else, the same questions apply. The legal status of a place is one signal. It's not the only signal, and sometimes not the most important one. Cost is real. So is travel. So is the question of how much time you can take afterward to actually let the experience land. A weekend session jammed between two stressful work weeks is a waste of money and an unkindness to yourself. I've sat across from a lot of people considering their first psychedelic retreat. The ones who tend to do well aren't the bravest or the most spiritually fluent. They're the ones who know why they're going. Not in a grand way — just specifically. “I want to look at what happened with my father.” “I want to know if I can stop drinking.” “I've been depressed for three years and nothing has moved.” A clear question makes for clearer work. The ones who struggle are usually running from something rather than toward something, or they've heard psilocybin called a miracle and they want the miracle. The medicine doesn't reward that posture. It tends to show people exactly what they've been avoiding, which is rarely comfortable and almost always useful in the long run. Oregon's experiment is still young. The price point will likely come down as more centers open and competition grows. The model itself — supervised, integrated, deliberately slow — is probably closer to what responsible psychedelic care looks like than either the underground or the pharma-clinical-trial extremes. Whether you go that route, choose a traditional ayahuasca retreat abroad, or stay home and read a few more books before deciding, the honest move is the same: get specific about what you want, get honest about your medical realities, and don't outsource the decision to a marketing brochure. If something here is sitting with you and you want to look at concrete options, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with it. The retreat will still be there next month, and the question of whether you're ready is worth more than a quick yes.
How Psychedelics Reshape the Brain: New Science on Depression and Healing
For a long time, the story we were told about depression was tidy and chemical. Your serotonin is low. Take this pill. Wait six weeks. Feel better. Except for millions of people, that script never quite worked — and the more neuroscientists look under the hood, the messier the actual picture becomes. Depression, it turns out, isn’t just a chemistry problem. It’s a structural one. And psychedelics, of all things, may be one of the most interesting tools we have for addressing it. That’s not a wellness-influencer claim. It’s where the lab work is pointing. Researchers studying psychedelics — LSD, psilocybin from magic mushrooms, DMT from ayahuasca, MDMA — have found that these compounds don’t just shift perception for a few hours. They appear to physically change the architecture of neurons themselves. And those changes look a lot like the opposite of what depression does to the brain. If you picture a neuron as a tree, its dendrites are the big branches reaching out toward other cells, and the tiny dendritic spines are the smaller offshoots that catch incoming signals. Neuroscientists genuinely borrow horticultural language for this — arbors, pruning, growth. The brain is, in a real sense, a forest that thins and thickens depending on how you live in it. In people with chronic depression, certain regions of that forest go quiet. The prefrontal cortex — the area that helps regulate mood, anxiety, and decision-making — shows atrophy. Branches shrivel. Spines disappear. Connections that used to fire together fall out of contact. This shrinkage correlates with the experience people describe in plain language: feeling flat, disconnected, locked in, unable to imagine anything different. The old chemical-imbalance story doesn’t really account for any of this. It treated the brain like a soup that needed reseasoning. What the structural research suggests is closer to a garden that’s been neglected through a long drought. You don’t fix a drought by adjusting one ingredient. You have to bring the system back to life. Here’s where it gets interesting. When researchers grow neurons in a dish and expose them to psychedelic compounds, the neurons sprout. More branches. More spines. More synaptic connections with neighboring cells. The same thing shows up in studies on fruit flies and rodents. The effect is fast — sometimes within 24 hours — and it lasts. Scientists have started calling these compounds psychoplastogens: substances that rapidly promote structural plasticity in the brain. The category includes the classic psychedelics (LSD, psilocybin, DMT), MDMA, and ketamine, which technically isn’t a psychedelic at all but produces eerily similar effects on neuronal growth. They appear to work, at least in part, by activating a protein called mTOR, which acts as a kind of master switch for cell growth. This matters because the brain changes don’t expire when the trip ends. The hallucinatory part of an ayahuasca night might last six or eight hours. The neural rewiring it kicks off seems to keep working for weeks. That timeline lines up with what people consistently report after well-held ceremonies — that the days and months afterward are when the real shifts happen, not the night itself. Ayahuasca is the most studied plant medicine in this space, partly because traditional Amazonian use has been documented for so long and partly because DMT — the active visionary alkaloid — is one of the more dramatic psychoplastogens in the lineup. A 2015 Brazilian study found that a single dose of ayahuasca produced fast-acting antidepressant effects within a day in patients with treatment-resistant depression. Not modest improvements over months. Same-day shifts. The Amazonian curanderos who work with ayahuasca, San Pedro, and other master plants would tell you none of this is news. They’ve been describing these medicines as plant teachers for generations — beings that show you what’s stuck, what needs tending, what wants to grow. The Western science just gives us a different vocabulary for the same observation: something about these compounds wakes the brain back up. It’s worth being honest, though. The lab data is exciting; it isn’t a guarantee. A neuron sprouting in a dish is not the same as a human being healing from twenty years of trauma. The ceremonial container, the integration afterward, the people you sit with — all of that matters enormously for whether the biological window the medicine opens turns into actual change. The same structural logic applies to addiction. Addictive behavior carves deep ruts in the brain — strong, well-worn neural circuits that fire reliably in response to certain cues. Conventional treatment tries to weaken those circuits gradually, through behavior change and abstinence. It works, but slowly, and relapse rates are brutal. Psychedelic-assisted recovery seems to work differently. By temporarily destabilizing the brain’s rigid patterns and encouraging new growth, plant medicines may give a person something closer to a window — a period where the old grooves loosen enough for new ones to form. Ibogaine, in particular, has shown striking results for opioid addiction. Ayahuasca and psilocybin have shown promise for alcohol dependence and tobacco cessation. MDMA-assisted therapy for PTSD is moving toward approval in several jurisdictions. None of this means you swallow a substance and your addiction lifts. The substance opens a door. Walking through it — with a skilled facilitator, a real preparation period, and a serious integration practice — is what does the work. The brain’s new growth needs somewhere to grow toward. Here’s the part the enthusiastic articles tend to gloss. Promoting rapid neural growth is a powerful intervention, and we don’t fully understand its long-term consequences. Excessive mTOR activity has been linked to other conditions, including some neurodevelopmental disorders. The same biological mechanism that may heal one brain in one context might do something else entirely in another. There are also the obvious considerations: And the experience itself isn’t gentle. Ayahuasca nights routinely involve purging, hours of intense visionary content, and moments most people would describe as the hardest thing they’ve ever done. The brain’s sudden plasticity is not a soft, fuzzy event. It’s a system being shaken loose. If you’ve read this far, you’re probably not casually curious. Most people researching plant medicine seriously are doing it because something in their life hasn’t shifted through the usual channels — therapy, medication, willpower, time. That’s a legitimate reason to look, but it also means the decision deserves more care than choosing a vacation. A few honest questions worth sitting with before booking anything: Cost varies wildly. A reputable ayahuasca retreat in Peru typically runs between $1,500 and $3,500 for a week, with luxury operations going much higher. Ibogaine clinics, because they require medical supervision, tend to start around $5,000 and climb. Cheaper isn’t always worse and expensive isn’t always better — what matters is the integrity of the people holding the space. The most ambitious researchers in this field are trying to engineer compounds that produce the neural growth without the hallucinations — a kind of psychoplastogen without the visionary night. Whether that’s desirable or whether it misses the point is one of the live debates in the space. Plenty of clinicians and traditional practitioners would argue that the subjective experience isn’t a side effect to be optimized away. It’s where the meaning gets made. For now, the practical situation is this: legal access to psychedelics is expanding (Oregon and Colorado have decriminalized or regulated psilocybin services; ayahuasca remains legal in Peru, Brazil, Costa Rica, and a handful of other places), the research keeps stacking up, and more people every year are deciding the risks of trying are smaller than the costs of staying stuck. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, treat it as a decision, not a leap. The brain is more plastic than we used to think. So is a life.
Inside Oregon's Legal Psilocybin Experiment: What It Means for Psychedelic Retreats
Something quietly historic is happening in Oregon. While most of the United States still treats psilocybin mushrooms as a Schedule I substance, this one state on the Pacific coast is busy building the country's first legal, regulated framework for psilocybin services. Not decriminalisation. Not a research carve-out. An actual, licensed system where adults can sit with psilocybin under the care of a trained facilitator. For anyone weighing a psychedelic retreat — especially folks who've been reading about psilocybin for depression, end-of-life anxiety, or stubborn patterns that no amount of talk therapy has shifted — Oregon matters. It's the closest thing we have to a working blueprint. And the people building it are doing so in real time, in public, with all the messiness that involves. Back in 2020, voters passed Measure 109, the ballot initiative that authorised the creation of a legal psilocybin services program. It didn't legalise mushrooms in the supermarket sense. What it did was open a narrow but very real door: adults aged 21 and over could, eventually, consume psilocybin at licensed service centres under the supervision of trained facilitators. No prescription required. No specific diagnosis required. That last part is what makes the Oregon model genuinely novel. Other psychedelic pathways being developed in the U.S. — MDMA for PTSD, psilocybin for treatment-resistant depression — are medical models, gated by diagnosis and FDA approval. Oregon's program is a services model. The state regulates training, product, and venues, but the experience itself sits closer to a ceremony than a clinic visit. That distinction matters more than it first appears. Two main bodies have done the heavy lifting. The Oregon Psilocybin Advisory Board drafted recommendations covering everything from facilitator training requirements to product testing standards. The Oregon Health Authority, through its Oregon Psilocybin Services division, turned those recommendations into actual rules. The first legal sessions began taking place in 2023, and the program has been expanding — and learning hard lessons — ever since. A program like this doesn't appear out of nowhere. It's the product of a small, identifiable group of people — campaign organisers, attorneys, regulators, therapists, and entrepreneurs — who spent years pushing the boulder up the hill. A few names worth knowing if you're trying to understand how this market actually works. Tom Eckert and the late Sheri Eckert were the chief petitioners behind Measure 109. Tom went on to chair the advisory board during the early rulemaking, then stepped away amid questions about board-member conflicts of interest — an early reminder that this industry has the same political mess as any other. He now directs work at InnerTrek, one of the larger psilocybin-facilitator training programs in the state, and at the Sheri Eckert Foundation, which funds scholarships for people who want to train as facilitators but can't afford the tuition. Sam Chapman managed the Measure 109 campaign and now leads the Healing Advocacy Fund, a nonprofit that's stayed deeply involved in implementation. David Bronner — yes, the soap guy — poured roughly $2 million of Dr. Bronner's money into passing the measure and has continued funding training programs, harm-reduction work, and equity initiatives. His company has put tens of millions into drug-policy reform over the years, which is not the kind of detail you forget once you've seen it on a bottle of peppermint castile. On the regulatory side, André Ourso and Angela Allbee at the Oregon Health Authority have been the people actually translating a ballot measure into a working program. Ourso previously oversaw the rollout of Oregon's cannabis market, which gave the state at least some institutional muscle memory for standing up a regulated controlled-substance industry. Allbee manages day-to-day operations of Oregon Psilocybin Services, which is the part of state government that issues the licences and writes the rules. One of the most interesting fights inside Oregon's program has been about facilitators — who they are, how they're trained, and how much it costs to become one. This isn't a side debate. It's the whole ball game. Jon Dennis, an attorney and cofounder of the Entheogenic Practitioners Council of Oregon, has been a persistent voice arguing that religious, spiritual, and community-based practitioners should have a meaningful role in the legal program. His worry — and it's a reasonable one — is that if facilitator training is structured like a graduate degree, with the price tag to match, the only people serving clients will be affluent therapists, and the cost of a session will price out the people who most need access. Angela Carter, a vice chair on the advisory board, has pushed similar equity and harm-reduction priorities from inside the regulatory process. At the same time, organisations like Fluence — cofounded by Ingmar Gorman and Elizabeth Nielson, both psychologists who worked on MDMA-assisted therapy trials — have been building rigorous clinical-style training programs aimed at therapists who want to add psilocybin work to their practice. Both visions are defensible. Both are getting built. How they coexist will shape what an Oregon psilocybin session actually feels like. Here's the practical takeaway for someone in the research phase. Oregon's legal program is not a retreat in the Costa Rica or Peruvian-jungle sense. Most licensed service centres offer a single session — preparation meeting, dosing day, integration meeting — rather than a multi-day immersive experience. Prices have settled in the rough neighbourhood of $1,000 to $3,500 for the full arc, depending on the facilitator, the venue, and the dose. That's lower than some international retreats and considerably higher than others. If you're weighing your options, a few honest things worth holding in mind: Colorado followed Oregon's lead with its own psychedelic-services initiative, passed in 2022 and now rolling out. Other states are watching closely, drafting bills, and quietly preparing legislation. The federal picture remains murky — psilocybin is still Schedule I, and the DEA hasn't softened its public stance — but the state-level momentum is real, and it's not slowing down. What Oregon proves, more than anything, is that a regulated psychedelic services market is possible. Not easy. Not without its conflicts of interest, equity gaps, and growing pains. But possible. For readers who've spent years assuming plant medicine meant flying to South America or knowing the right underground guide, that's a meaningful shift. It's also worth saying plainly: a legal framework doesn't make psilocybin right for everyone. People on certain antidepressants, people with personal or family histories of psychosis, people in acute crisis — these are situations where a thoughtful provider will tell you to wait, or to look at other tools first. The most useful question isn't where to do this work but whether now is the time, and with what kind of support around you. If you're somewhere in that weighing phase, it can help to see what's actually on offer — different settings, different traditions, different price points — before committing to anything. A curated set of psilocybin and plant-medicine retreats can be browsed on our marketplace here, which is a low-pressure way to compare what's out there while you keep doing your homework. Oregon's experiment is young. The facilitators are still learning. The regulators are still adjusting. But the door is open in a way it wasn't five years ago, and the people who pushed it open deserve some credit for that — even when the politics behind the scenes have been less than tidy.
Ketamine for Depression: What the Latest Trial Results Mean
Ketamine, a medication primarily used as an anesthetic, has been explored as a potential treatment for severe forms of depression. Its fast-acting nature makes it an attractive option for patients experiencing sudden bouts of suicidality. However, the latest trial results from Atai Life Sciences, a leading company in the field of psychedelics, have raised questions about its efficacy. The trial, conducted by Perception Neuroscience, a subsidiary of Atai, involved 102 patients with treatment-resistant depression. These patients were administered either a 60mg dose of PCN-101, a 30mg dose, or a placebo. The results showed that patients who received the 60mg dose did not experience significant improvement in their depression symptoms compared to those who received the placebo. This outcome is particularly noteworthy given the current landscape of depression treatment. With many patients not responding to traditional therapies, the search for alternative treatments is urgent. Ketamine, with its unique mechanism of action, had been seen as a promising candidate. The failure of this trial, however, underscores the complexity of treating depression and the need for continued research. The trial's methodology involved administering the drug intravenously and then assessing the patients' depression symptoms 24 hours later using the Montgomery-Åsberg Depression Rating Scale. The lack of significant improvement in the treatment group compared to the placebo group is a critical finding. It suggests that, at least in the context of this study, ketamine may not offer the therapeutic benefits that were hoped for. The implications of this trial are multifaceted. For patients and their families, the news may be disappointing, especially for those who have been waiting for new treatment options. For the field of psychedelic research, this trial serves as a reminder of the challenges involved in developing effective treatments. It highlights the need for rigorous scientific testing and the importance of not overstepping the bounds of current evidence. Atai Life Sciences has announced plans to continue reviewing the data from the trial to determine the next steps. This approach is prudent, given the potential that subgroup analyses or further research could uncover beneficial effects that were not immediately apparent. Ketamine is not the only psychedelic compound being explored for its therapeutic potential. Psilocybin, the active ingredient in magic mushrooms, and MDMA, commonly known as ecstasy, are also under investigation for their possible roles in treating mental health disorders. The journey of these substances from recreational drugs to potential therapeutic agents is a complex one, marked by both promise and challenge. The approval of Spravato, a drug based on ketamine, by the FDA in 2019 for the treatment of severe depression, marked a significant milestone in this journey. It demonstrated that, with rigorous testing and regulatory approval, psychedelic-derived medicines could enter the mainstream of psychiatric treatment. However, the path forward is not without its obstacles. Regulatory hurdles, public perception, and the need for high-quality clinical trials are just a few of the challenges that must be overcome. The recent trial results, while disappointing, are a part of this process. They contribute to the growing body of evidence that will eventually guide the development and use of psychedelic medicines. The latest trial results on ketamine's effectiveness in treating depression are a sobering reminder of the complexities and challenges inherent in psychiatric research. While they may dampen some of the enthusiasm surrounding psychedelic medicine, they do not diminish the potential that these substances hold. Instead, they underscore the importance of a cautious, evidence-based approach to developing new treatments. As the field of psychedelic medicine continues to evolve, it is crucial that researchers, clinicians, and patients remain committed to the principles of rigorous scientific inquiry and patient safety. The future of psychedelic medicine is promising, but it must be built on a foundation of solid evidence and careful consideration of both the benefits and the risks of these powerful substances.
What Ibogaine Actually Teaches You: Lessons From the Other Side of Treatment
People come to ibogaine for one reason, usually. They want the addiction to stop. Whether it's heroin, fentanyl, methadone, alcohol, or some tangled combination, the pitch is almost too clean: one long session with a powerful African root, and the withdrawal vanishes. The cravings quiet down. The story ends. Except it doesn't end. That's the part nobody puts on the retreat brochure. Ibogaine isn't a finish line — it's a strange, exhausting, sometimes unbearable doorway. And what people actually learn on the other side of it is often very different from what they expected to learn. This piece is for anyone weighing ibogaine treatment for addiction, or trying to understand what a friend or family member just went through. Plant medicine doesn't hand you a new life. It hands you information. What you do with it is the rest of the work. Ibogaine is a psychoactive alkaloid found in the root bark of Tabernanthe iboga, a shrub native to West Central Africa. The Bwiti tradition in Gabon has used iboga ceremonially for generations — initiation, ancestor work, deep personal reckoning. Outside that context, ibogaine became known in the West for something more specific: it appears to dramatically interrupt opioid withdrawal and reset the brain's response to certain addictive substances. The mechanism is still being studied, but the lived experience is striking. People who've been physically dependent for years describe walking out of a session without the bone-deep sickness they expected. Cravings, in many cases, drop to a whisper. That's the part that gets attention — and rightly so. For someone who's been trapped in a cycle, the idea that one treatment could break the physical hold is staggering. But here's where the misunderstanding starts. Interrupting withdrawal is not the same as curing addiction. The substance does something profound to your nervous system. It does not, on its own, repair the reasons you started using in the first place. Most psychedelic experiences clock in at four to eight hours. Ibogaine runs longer — often 24 to 36 hours from first dose to the point you can walk steadily again. The first phase is sometimes called the visionary state, and it's where the famous “life review” happens. Memories surface, sometimes in vivid sequence, sometimes scattered. People describe watching their lives from the outside, observing choices they'd buried for decades. The second phase is more cognitive — quieter, more reflective. You're processing what came up. The body is doing heavy lifting too: ibogaine slows the heart rate significantly, which is why reputable clinics require an EKG, blood work, and continuous cardiac monitoring. This is not a substance to take in a friend's living room. The cardiac risks are real, and most ibogaine-related fatalities trace back to inadequate medical screening. By the third phase, you're tired in a way you've probably never been tired. People talk about a kind of grey clarity that lasts for days. The body is exhausted; the mind is unusually quiet. And then — this is the part nobody warns you about enough — you have to go home. If you read enough first-person accounts, certain themes show up over and over. Not in the marketing copy. In the honest reports — the ones written months or years later, when the dust has settled. That last point is the one most people underestimate. The session is dramatic. The integration is mundane. And mundane is what changes a life. This question comes up constantly from people researching plant medicine for addiction, so it's worth addressing directly. Both ayahuasca and ibogaine have been studied as tools for addiction recovery, and both have produced remarkable case reports. They are not interchangeable. Ibogaine is, by most accounts, the more medically demanding of the two. The cardiac risk is higher. The session is longer. It's particularly effective at interrupting opioid dependence — something ayahuasca generally is not designed to do. If your primary issue is physical dependence on opioids, ibogaine is the more direct intervention. Ayahuasca tends to work differently. It's better suited to longer-arc work — depression, trauma, behavioural addictions, alcohol patterns, the existential layer of why-am-I-like-this. Many people who first encounter plant medicine through ibogaine eventually find their way to ayahuasca ceremonies for ongoing integration work. The two can complement each other across years, not weeks. Master plants — the broader category these medicines fall into — share something important: they show you things. They don't decide for you. Whichever path fits your situation, the work after the ceremony is what determines the outcome. This is where I get blunt. The ibogaine world has reputable clinics doing careful, life-saving work. It also has cowboys. The difference between the two can be the difference between recovery and a coroner's report. If you're seriously considering treatment, look for these markers: Mexico and Costa Rica host most of the legal, medically-supervised clinics serving North Americans, since ibogaine is unscheduled in those countries. The legal status in the United States is more restrictive — ibogaine is a Schedule I substance there — which is why most treatment-seekers travel. If you're reading this because you or someone you love is stuck in addiction, here's the honest path forward. Do your research slowly. Talk to people who've been through it — not just the ones the clinics put forward, but the harder-to-find ones who'll tell you what didn't work. Get a real medical workup before you commit. Build your aftercare plan before you book the session, not after. And don't expect ibogaine to do the work that therapy, community, and time are supposed to do. The people who do well with ibogaine treatment tend to share a particular quality: they treat it as the beginning of something, not the end. They line up integration support, change their environment, take the post-session window seriously, and accept that the medicine has shown them what to do — but it's still on them to do it. If something here resonates and you want to explore further, a curated selection of ibogaine and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The right retreat, at the right moment, with the right aftercare around it — that's what changes things. Not the medicine alone.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
